Nimbus site 117 — Jackson, Tennessee

Nimbus site 117 is a clinical research site located in Jackson, Tennessee, United States 38305.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Nimbus site 117 has participated in 1 clinical trials.

Therapeutic areas: Moderate to Severe Plaque Psoriasis.

Sponsors: Takeda.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Jackson

Browse all research sites in Tennessee · View every site in Jackson

• Kirkland Cancer Center/Jackson Madison County General Hospital
• Jackson-Madison Hospital
• Jackson-Madison County General Hospital
• Regional Hospital
• Jackson-Madison County Hospital
• Western TN- Jackson-Madison County General Hospital
• West Tennessee Cancer Center at Jackson-Madison County General Hospital
• Jackson General Hospital
• University of Tennessee Family Practice Center
• West Tennessee Research Institute
• Research Site
• The Jackson Clinic PA

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Nimbus site 117?

Nimbus site 117 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Nimbus site 117 conducted?

Nimbus site 117 has 1 clinical trials on record. Their work covers Moderate to Severe Plaque Psoriasis.

Is Nimbus site 117 accredited by Crixeo Clinical Trials?

Nimbus site 117 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Nimbus site 117?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.